regulatory

News

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

AstraZeneca will hear back from the FDA in the first quarter of next year about its recent filing of Tagrisso in combination with chemotherapy as a first-line treatment fo

News

MHRA pledges two-week review for low-risk clinical trials

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has implemented one part of its plan to reform the regulations governing clinical trials, namely an ini

News

FDA will add digital health advisory committee to its roster

The FDA is setting up a new advisory committee to provide independent expertise on the emerging category of technologies like digital therapeutics, virtual and augmented r

News

Alnylam’s expansion plan for Onpattro blocked by FDA

Alnylam has abandoned plans to add cardiomyopathy to the label for transthyretin-mediated amyloidosis (ATTR) therapy Onpattro after the FDA turned down its marketing appli

News

FDA panel sceptical on Lumakras confirmatory data

An FDA advisory committee has voted that Amgen’s confirmatory phase 3 trial for KRAS inhibitor Lumakras is not enough to support full approval, but it seems unlikely that

News

Takeda pulls Exkivity in US after failed confirmatory trial

Takeda has decided to withdraw its cancer drug Exkivity from the market, after a trial that was supposed to confirm its efficacy failed to deliver a positive result.

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

MHRA pledges two-week review for low-risk clinical trials

FDA will add digital health advisory committee to its roster

Alnylam’s expansion plan for Onpattro blocked by FDA

FDA panel sceptical on Lumakras confirmatory data

Takeda pulls Exkivity in US after failed confirmatory trial

On AI and computational support of biochemistry, with Alan R...

The AI imperative: Establishing the standard for modern clin...

regulatory

Editor's Picks